Sahar Mazhar

Sahar Mazhar has a diverse work experience in the field of scientific research. Starting in 2010, Sahar worked as an Associate Researcher I at the Icahn School of Medicine at Mount Sinai, where they investigated the molecular mechanism of the tumor suppressor KLF6 and contributed to the development of SMAPs. They then moved on to work as a Graduate Student Researcher at Case Western Reserve University from 2012 to 2020. During this time, Sahar conducted various studies on the role of germline variants in the PP2A family of phosphatases in cancer predisposition. They also investigated the anti-tumor efficacy of Small Molecule Activators of PP2A (SMAP) in different malignancies. Sahar's work at Case Western Reserve University resulted in multiple publications. In 2018, Sahar became a Visiting Graduate Student at Michigan Medicine - Division of Genetic Medicine, and in 2020, they joined Rappta Therapeutics as a Consultant. Currently, Sahar holds the position of Staff Scientist at Nitrase Therapeutics, where they continue their research in the field of science.

Sahar Mazhar pursued their education in a chronological manner. Sahar began their academic journey in 2005 at Ohio Wesleyan University, where they completed their Bachelor of Arts degree in 2009. The field of study for their bachelor's degree is not mentioned. Later, they enrolled at Case Western Reserve University in 2014 and completed their Doctor of Philosophy (PhD) degree in the field of Pathology, specifically the Cancer Biology Training Program, in 2020.